Physician profile
Dendy E Engelman
NPI 1326129990
$291,564.45
in general payments reported to CMS, 2019-2025
23 companies · $62K in 2025
The $62K reported for 2025 was more than what 96% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $48K · 2021: $24K · 2022: $64K · 2023: $27K · 2024: $28K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $105K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,612 · Travel and Lodging: $1,224 · Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $105,432.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,612.00 |
| Travel and Lodging | $1,223.50 |
| Food and Beverage | $899.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $157,743.34 | 2019-2022 | |
| Abbvie INC. | $107,789.53 | 2019-2025 | |
| Galderma Laboratories, L.P. | $12,038.51 | 2019-2025 | |
| Merz North America, INC. | $8,712.67 | 2020-2022 | |
| Endo Pharmaceuticals INC. | $4,193.70 | 2019 | |
| Leo Pharma INC. | $184.84 | 2019-2025 | Anzupgo |
| Novartis Pharmaceuticals Corporation | $121.14 | 2019 | |
| Celgene Corporation | $120.72 | 2019 | |
| Lilly USA, LLC | $82.57 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.95 | 2020 | |
| Mayne Pharma Commercial LLC | $73.27 | 2019 | |
| Sun Pharmaceutical Industries INC. | $68.92 | 2019-2020 | |
| Acelrx Pharmaceuticals, INC. | $62.44 | 2021-2022 | |
| Sandoz INC. | $49.80 | 2019 | |
| Pfizer INC. | $42.23 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taro Pharmaceuticals USA, INC. | $41.10 | 2019 | |
| Genzyme Corporation | $38.96 | 2020 | |
| Almirall LLC | $22.81 | 2019 | |
| Dermira, INC. | $22.48 | 2020 | |
| Sanofi-Aventis U.S. LLC | $21.09 | 2020 | |
| Epi Health, LLC | $20.41 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $19.61 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $18.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dendy Engelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.